Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MorphoSys Is At BIO Looking To Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

Flush German biotech looks to in-license or acquire clinical stage biologics to even out its pipeline as it edges from fee-for-service to development business model.

You may also be interested in...



MorphoSys Fills Out Pipeline With Xencor Deal

After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.

MorphoSys Fills Out Pipeline With Xencor Deal

After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.

Novartis Deepens Its Commitment To Biologics With MorphoSys Deal Worth Up To $1 Billion

German mAb company’s single-partner plan includes letting deals expire with other pharmas such as Bayer Schering and J&J, as well as upping internal pipeline investments.

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel